2 results match your criteria: "Karolinska University Hospital HuddingeStockholm[Affiliation]"
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.
Front Pharmacol
September 2016
Health Economics Centre, University of Liverpool Management SchoolLiverpool, UK; Department of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of StrathclydeGlasgow, UK; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital HuddingeStockholm, Sweden.
Payers are a major stakeholder in any considerations and initiatives concerning adaptive licensing of new medicinal products, also referred to as Medicines Adaptive Pathways to patients (MAPPs). Firstly, the scope and necessity of MAPPs need further scrutiny, especially with regard to the definition of unmet need. Conditional approval pathways already exist for new medicines for seriously debilitating or life-threatening diseases and only a limited number of new medicines are innovative.
View Article and Find Full Text PDFIntroduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future.
Front Pharmacol
August 2016
Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital HuddingeStockholm, Sweden; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of StrathclydeGlasgow, UK.
Background: Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients.
View Article and Find Full Text PDF